Medical Science
| Open Access |
DOI: Genetic Polymorphism of The Natriuretic Peptide System and Long-Term Outcomes of Coronary Artery Stenting
Azizov Shuxratjon Ismatjonovich , Assistant, Department of Internal Medicine, Nephrology and Hemodialysis, Tashkent State Medical University, Tashkent, UzbekistanAbstract
The study evaluated the association between genetic polymorphisms of the natriuretic peptide system and long-term outcomes after coronary artery stenting. A total of 112 patients with coronary artery disease who underwent drug-eluting stent implantation were examined. Genetic testing included NPPA rs5065, NPPB rs198389, and NPR3 rs2270915 polymorphisms. The follow-up period was 24 months. Major adverse cardiovascular events were observed in 28 patients, recurrent angina in 31 patients, in-stent restenosis in 17 patients, and repeat revascularization in 14 patients. NPPA rs5065 C allele carriage was associated with a higher risk of adverse cardiovascular events, while NPR3 rs2270915 G allele carriage was associated with in-stent restenosis. NPPB rs198389 C allele carriage was associated with increased NT-proBNP levels.The results indicate that polymorphisms of the natriuretic peptide system may be useful markers for risk stratification and personalized follow-up after coronary artery stenting.
Keywords
Coronary artery disease, coronary stenting, natriuretic peptides
References
Lawton J.S., Tamis-Holland J.E., Bangalore S., Bates E.R., Beckie T.M., Bischoff J.M., et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. Circulation. 2022;145(3):e18–e114.
Neumann F.J., Sousa-Uva M., Ahlsson A., Alfonso F., Banning A.P., Benedetto U., et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal. 2019;40(2):87–165.
Vrints C., Andreotti F., Koskinas K.C., Rossello X., Adamo M., Ainslie J., et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. European Heart Journal. 2024;45(36):3415–3537.
Verschuren J.J.W., Trompet S., Postmus I., Sampietro M.L., Heijmans B.T., Houwing-Duistermaat J.J., et al. Systematic Testing of Literature Reported Genetic Variation Associated with Coronary Restenosis: Results of the GENDER Study. PLoS ONE. 2012;7(8):e42401.
Liu Y.W., Huang M.S., Hsu L.W., Chang H.Y., Lee C.H., Lee C.Y., et al. Genetic risk model for in-stent restenosis of second- and third-generation drug-eluting stents. iScience. 2021;24(10):103082.
Newton-Cheh C., Larson M.G., Vasan R.S., Levy D., Bloch K.D., Surti A., et al. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nature Genetics. 2009;41(3):348–353.
Cannone V., Boerrigter G., Cataliotti A., Costello-Boerrigter L.C., Olson T.M., McKie P.M., et al. A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community. Journal of the American College of Cardiology. 2011;58(6):629–636.
Seidelmann S.B., Vardeny O., Claggett B., Yu B., Shah A.M., Ballantyne C.M., et al. An NPPB promoter polymorphism associated with elevated N-terminal pro-B-type natriuretic peptide and lower blood pressure, hypertension, and mortality. Journal of the American Heart Association. 2017;6(4):e005257.
Pereira N.L., Redfield M.M., Scott C., Tosakulwong N., Olson T.M., Bailey K.R., et al. A Functional Genetic Variant N521D in Natriuretic Peptide Receptor 3 Is Associated with Diastolic Dysfunction: The Prevalence of Asymptomatic Ventricular Dysfunction Study. PLoS ONE. 2014;9(1):e85708.
Saulnier P.J., Roussel R., Halimi J.M., Lebrec J., Doussau A., Ragot S., et al. Impact of natriuretic peptide clearance receptor polymorphism on systolic blood pressure in patients with type 2 diabetes. Diabetes Care. 2011;34(5):1199–1204.
Download and View Statistics
Copyright License
Copyright (c) 2026 Azizov Shuxratjon Ismatjonovich
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.